Navigation Links
Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade

ST. LOUIS, Jan. 8 /PRNewswire-FirstCall/ -- Substantial progress and momentum behind its research-and-development (R&D) pipeline has Monsanto (NYSE: MON) poised to deliver several new blockbuster products to farmers by 2012, company leaders will tell investors today. The remarks will come as part of a series of presentations on the company's R&D pipeline in New York and Boston.

"It's rewarding to see such innovation in the pipeline right now," said Steve Padgette, vice president of biotechnology for Monsanto. "This is the most progress I've seen in my 23 years at the company. Our data demonstrates these cutting-edge innovations can deliver new value to farmers well into the next decade."

As part of the presentations, scheduled over the next two days, Padgette will discuss the progress and momentum behind a number of key projects in the R&D pipeline. Key highlights include:
-- YieldGard VT PRO, one of the primary components of SmartStax

technology, is primed to offer farmers a broader spectrum of insect

control and improved durability when compared with the company's

first-generation corn borer offering. The second-generation corn borer

technology is in Phase IV of the company's R&D pipeline and currently

awaiting regulatory approvals.

-- YieldGard Rootworm III is designed to provide two modes of action for

improved spectrum control and enhanced durability against the corn

rootworm pest. The technology incorporates cutting-edge RNA

interference (RNAi) technology and novel protein identification. RNAi

is a mechanism used naturally by cells to regulate gene expression. By

harnessing this natural machinery, RNAi technology can help plants

protect themselves from insects.

-- Omega-3 enriched soybeans, which are expected to offer a land-based

source of essential Omega-3 fatty acids, continues to demonstrate

comparable consumer acceptability in recent results between SDA soy oil

and conventional soy oil in food uses. The product also continues to

demonstrate solid yield performance when compared to controls.

-- Drought-tolerant cotton, which is designed to minimize risk in cotton

farming by providing yield stability in water stressed environments,

demonstrated strong performance across multiple gene leads. With these

results in hand, Monsanto now believes there are a number of product

leads to create a family of drought traits in cotton.

A live webcast of Monsanto's R&D presentations will be available through Monsanto's web site at: Following the live broadcast, a replay of the webcast will be available on the Monsanto web site for two weeks. To access presentation slides and the simultaneous audio webcast of the presentation, visitors may need to download Windows Media Player(TM) prior to listening to the webcast.

To listen to comments from Padgette and Robb Fraley, Monsanto's chief technology officer and executive vice president, on the progress in the pipeline, please visit:

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information, please visit:

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this presentation are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits, including proceedings related to Solutia Inc.; developments related to foreign currencies and economies; successful completion and operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this presentation. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

SOURCE Monsanto
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
3. Michigan Life Sciences Pipeline to Kick Off MichBio Expo
4. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on for Media and Professional Use
5. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
6. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
7. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
8. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
11. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):